» Articles » PMID: 10982289

Complications After Bone Marrow Transplantation Are Manifestations of Systemic Inflammatory Response Syndrome

Overview
Specialty General Surgery
Date 2000 Sep 12
PMID 10982289
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Bone marrow transplantation has been established as a useful treatment for various hematological disorders and is now performed widely, but the mortality rate is still high due to various complications. A clear therapeutic policy for such complications has not yet been established because of their complex nature. We investigated whether the major complications occurring after bone marrow transplantation could be classified as aspects of the systemic inflammatory response syndrome. Subjects were 10 patients who developed severe complications after bone marrow transplantation (graft-versus-host disease, thrombotic microangiopathy, respiratory disorders, and cytomegalovirus interstitial pneumonitis) and 16 patients without complications. Their symptoms, serum cytokines, and factors related to vascular endothelial damage were compared before and after transplantation. Whereas all 10 patients who developed complications had fever in the aplastic phase after transplantation, 15 of the 16 patients without complications remained afebrile (P < 0.001, t-test). When compared with the patients who did not develop complications, the patients with complications also showed significantly higher cytokine levels during the recovery phase after transplantation (P < 0.0001, t-test). Thus, the patients with complications developed fever in the aplastic phase and showed an increase of cytokines during the recovery phase, which triggered the occurrence of vascular endothelial damage shown by factors such as the thrombomodulin and plasminogen activator inhibitor type 1. This sequence of events corresponds with that occurring during systemic inflammatory response syndrome, so many of the complications of bone marrow transplantation can be considered as manifestations of this syndrome.

Citing Articles

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.

Sorum M, Gang A, Tholstrup D, Gudbrandsdottir S, Kissow H, Kornblit B BMJ Open. 2024; 14(10):e089862.

PMID: 39384243 PMC: 11474865. DOI: 10.1136/bmjopen-2024-089862.


Upregulation of Insulin-like Growth Factor-I in Response to Chemotherapy in Children with Acute Lymphoblastic Leukemia.

Kocadag H, Weischendorff S, De Pietri S, Nielsen C, Rathe M, Als-Nielsen B Int J Mol Sci. 2024; 25(17).

PMID: 39273528 PMC: 11394967. DOI: 10.3390/ijms25179582.


Neurological involvement in hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Liu W, Zhu X, Xiao Y Ann Hematol. 2024; 103(9):3303-3313.

PMID: 38763940 PMC: 11358180. DOI: 10.1007/s00277-024-05798-6.


Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation.

Ebbesen M, Kissow H, Hartmann B, Kielsen K, Sorensen K, Stinson S Front Immunol. 2021; 12:793588.

PMID: 34956226 PMC: 8692255. DOI: 10.3389/fimmu.2021.793588.


Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.

Young J, Pallas C, Knovich M Bone Marrow Transplant. 2021; 56(8):1805-1817.

PMID: 33875812 PMC: 8338557. DOI: 10.1038/s41409-021-01283-0.